Telix Pharmaceuticals Balance Sheet Statement

TLX A$3.83 -0.1 -2.5%

26/02/21

Adventurous, Mid Cap, Momentum Trap

Market Cap £545.8m

Enterprise Value £533.9m

Revenue £1.84m

Quality

Value

Momentum

StockRank™

To unlock Telix Pharmaceuticals's balance sheet statement please upgrade your membership.

	2017	2018	2019
Period End:	2017-12-31	2018-12-31	2019-12-31
Period Length:	0	0	0
Currency:	AUD	AUD	AUD

Cash
Cash and Short Term Investments
Accounts Receivable - Trade, Net
Total Receivables, Net
Total Inventory
Prepaid Expenses
Other Current Assets, Total
Total Current Assets

Property/Plant/Equipment, Total - Gross
Accumulated Depreciation, Total
Property/Plant/Equipment, Total - Net
Goodwill, Net
Intangibles, Net
Note Receivable - Long Term
Other Long Term Assets, Total
Total Assets

Accounts Payable
Accrued Expenses
Notes Payable/Short Term Debt
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total
Total Current Liabilities

Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Other Liabilities, Total
Total Liabilities

Common Stock
Retained Earnings (Accumulated Deficit)
Other Equity, Total
Total Equity

Total Liabilities & Shareholders’ Equity
Total Common Shares Outstanding

Unlock Stockopedia Premium for free!

See what it can do for your stockpicking and portfolio at no expense.